TEI-3096: An immunopharmacological profile

概要

論文の詳細を見る
TEI-3096 (6-p-chlorobenzyl-5H-2, 3, 6, 7-tetrahydro-5, 7-dioxothiazolo (3, 2-a) pyrimidine), a novel thiazolopyrimidine compound has been shown to suppress adjuvant arthritis in rats without any effect on conventional inflammation. We examined the immunopharmacological profile of TEI-3096 in murine lymphocytes. The blastformation induced by Con A or LPS was inhibited by addition of 5×10-5-5×10-4 M concentrations of TEI-3096. This compound suppressed plaque-forming cell (PFC) response against sheep red blood cells (SRBC), a thymus-dependent antigen, irrespective of the concentrations of 2-mercaptoethanol (2-ME) in the culture medium. The suppressive effect was observed only when the drug was added to the medium within 48 hr after culture initiation. TEI-3096, however, produced either enhancement or suppression of PFC response to DNP-Ficoll, a thymus-independent antigen, depending on the dose of 2-ME. Repeated administration of TEI-3096 by oral route showed no significant effects on anti-SRBC PFC response in normal mice. However, this compound restored the colchicine-induced enhancement of antibody response against TNP-HGG. These results suggested that TEI-3096 might be interesting in that enhanced immune responses caused by immunological disorders might be normalized and might be useful for the treatment of autoimmune disease such as rheumatoid arthritis.
日本炎症・再生医学会の論文